CML Partnership 091012

Adding avelumab to carboplatin plus paclitaxel appears to elicit a progression-free survival advantage compared with chemotherapy alone in those with advanced or recurrent endometrial cancer.

Minh-Tri Nguyen, MD, spoke with CancerNetwork® about differences between time to treatment, socioeconomic status, and clinical outcomes in rural and urban patients with breast cancer.

Javier Orozco-Mera, MD, FACS, MSc, and colleagues assess the signaling pathways and molecular mechanisms involved in the relapse of glioblastoma.

Experts from Emory Winship Cancer Institute discuss how the FDA approval of sacituzumab govitecan will impact the treatment of breast cancer.

Findings from a cohort of the Childhood Cancer Survivor Study identify a prediction model that may accurately identify childhood cancer survivors at varying risks of late kidney failure.

Human papillomavirus and p16 discordance may correlate with a worse prognosis for oropharyngeal cancer, according to data from an individual patient data analysis.